Follow up study of children conceived following a lipiodol HSG (hysterosalpingogram)

Not Applicable

• Conditions: Cognitive development; Neurological - Studies of the normal brain and nervous system; Reproductive Health and Childbirth - Other reproductive health and childbirth disorders

• Registration Number: ACTRN12621000094875
• Lead Sponsor: niversity of Auckland, office of research strategy and integrity

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-02-01
• Last Update Posted: 20 June 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Exposure group: Children who are aged between 6-14 years, and have been conceived within 6 months of their mother receiving lipiodol hysterosalpingogram (HSG).

Control group: children who are aged between 6-14 years and are siblings of a child in the exposure group. They have been conceived without any assisted reproductive technology.

Exclusion Criteria

Overt, pre-existing developmental delay.
Chronic illness that can impact on developmental assessment.
Medication known to affect neurocognitive outcome such as anti-depressives, methylphenidate etc.
A history of recreational drug use including tobacco and alcohol.
Known bone fragility disorders or medical conditions that could affect bone density.
Twins conceived following lipiodol.

Study & Design

• Study Type: Observational
• Study Design: Not specified